News, Reports and Commentaries
Following are brief articles, reports, summaries, overviews and commentaries of research related to Fragile X-associated Disorders. The National Fragile X Foundation posts content only from reputable researchers or research institutions. In cases where summaries or overviews are provided, they are written for the NFXF by members of our Scientific & Clinical Advisory Committee or other members of the Fragile X research community. These are designed to acquaint the reader with the latest research information while providing a balanced assessment of its relevance to the treatment and eventual cure expected for Fragile X. Whenever possible, we will provide a link to a more detailed source of information for those who wish to understand the more technical aspects of the research findings. Commentary and opinion pieces are included whenever we feel they add to the thoughtful discussion and greater understanding of research.
Latest News
-
Posted at May 16, 2013 | Categories : Keeping You Informed,News Reports and Commentaries,Seaside STX209 | 28 Comments -
Kennedy Krieger in MD Looking for Children 5-13 with Fragile X Syndrome
Got Fragile X? Participate in a New Clinical Trial for Children with Fragile X Syndrome! Kennedy Krieger Institute is looking for children, ages 5 through 13 years, with fragile X syndrome to participate in a research study. Purpose The purpose of this study is to determine if an investigational drug is a safe and effective treatment for symptoms associated with fragile X syndrome. Procedures
. . . Read More: Kennedy Krieger in MD Looking for Children 5-13 with Fragile X Syndrome
-
Sertraline Study for 24-60 Month Old Children with Fragile X Syndrome
Sertraline Study - Clinical Trials We are actively recruiting children diagnosed with FXS between 24-60 months old to participate in a groundbreaking study! We have preliminary evidence that sertraline, a selective serotonin reuptake inhibitor (SSRI) is beneficial for langauge development in young children with FXS. It is our hope that this study will lead to a
. . . Read More: Sertraline Study for 24-60 Month Old Children with Fragile X Syndrome
-
New Research Leads to Better Understanding of FXTAS
The NFXF was excited to read this announcement from the University of Michigan Health System. There are a number of dedicated scientists and clinicians working on FXTAS, however new treatments have been slower in coming than for fragile X syndrome.
. . . Read More: New Research Leads to Better Understanding of FXTAS
Posted at April 22, 2013 | Categories : FXTAS,In the News,News Reports and Commentaries | 11 Comments -
Public Policy at Work: Abbeduto Given $3M NICHD Grant to Study Fragile X
The UC Davis MIND Institute reported on its website that a $3 million grant will allow their research team to investigate the effectiveness of testing procedures to examine the spoken language development of people with fragile X syndrome and people with Down syndrome. The grant was awarded by the Eunice Kennedy Shriver National Institute of Child Health and the Human Development of
. . . Read More: Public Policy at Work: Abbeduto Given $3M NICHD Grant to Study Fragile X
Posted at March 27, 2013 | Categories : 2013,News Reports and Commentaries,Public Policy and Legislative Advocacy | 6 Comments -
Research: Did You Grow Up in Iowa, or Know Someone Who Did?
You can help us discover more about fragile X syndrome and the FMR1 premutation! Our research team at Northwestern University is studying language and social characteristics related to the gene involved in fragile X syndrome, FMR1. We are looking at very subtle characteristics among carriers of the FMR1 premutation to help us understand more clearly how
. . . Read More: Research: Did You Grow Up in Iowa, or Know Someone Who Did?
-
Researchers Reverse Fragile X Syndrome Symptoms in Adult Mice, Promising Autism Treatment
“These findings suggest a possible novel therapeutic target for the treatment of Fragile X Syndrome (FXS) — the most common inherited form of autism and intellectual disability,” said Eric Klann, a professor of neural science at New York University.
. . . Read More: Researchers Reverse Fragile X Syndrome Symptoms in Adult Mice, Promising Autism Treatment
-
CIDD at UNC Chapel Hill: Looking for Infants with FXS Between 0-6 Months of Age
The Carolina Institute for Developmental Disabilities (CIDD) at the University of North Carolina at Chapel Hill would like to inform you of an exciting new research opportunity available to families with infants who have a child diagnosed with fragile X. This multi-center study involves the collaboration of two sites which are part of an
. . . Read More: CIDD at UNC Chapel Hill: Looking for Infants with FXS Between 0-6 Months of Age
-
Research: Seeking Fragile X Premutation Carriers for a Study of Cognition
Fragile X Spectrum as a Model to Explore Neurogenetic Mechanisms of Cognitive Dysfunction Funded by the National Institutes of Health Approved by the University of California, Davis Institutional Review Board (#221039-3) Researchers at the UC Davis MIND Institute (Tony J. Simon, PhD, Principal Investigator and Susan M. Rivera, PhD, Co-Principal Investigator) invite you to consider participating in a research
. . . Read More: Research: Seeking Fragile X Premutation Carriers for a Study of Cognition
-
Research: Study for Medication at University of Louisville
Do you have fragile X syndrome? Are you the parent or caregiver of a person with fragile X syndrome, or know someone who is? The Kosair Charities Pediatric Clinical Research Unit at the University of Louisville invites adolescents and adults with Fragile X Syndrome to take part in a research study for a medication that
. . . Read More: Research: Study for Medication at University of Louisville
Stay Connected
Seaside Therapeutics Announces End of Arbaclofen (STX209) Extension Study
Late yesterday afternoon the NFXF, along with all of the study locations, was contacted by Seaside Therapeutics and informed that the “Study 209FX303 [An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (arbaclofen) in Subjects with Fragile X Syndrome] is being terminated. The closure of the study is due to resource limitations at Seaside Therapeutics, Inc., and is not related to
. . . Read More: Seaside Therapeutics Announces End of Arbaclofen (STX209) Extension Study